Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results

Detalhes bibliográficos
Autor(a) principal: Magro,Fernando
Data de Publicação: 2012
Outros Autores: Cravo,Marilia, Lago,Paula, Ministro,Paula, Peixe,Paula, Portela,Francisco, Ramos,Jaime, Tavares,Lourdes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005
Resumo: Introduction: The treatment of inflammatory bowel disease (IBD) has focussed on the management of symptoms but is becoming more resolute on changing the course of the disease and its complications in the long-term. In order to minimize the development of complications and to improve outcomes for these patients it is important to develop other strategies to manage IBD and to optimize current clinical practice. Objective: This article reports the main consensus statements reached during the Portuguese National Meeting on improvement of disease control in IBD, on optimization of corticosteroid and immunosuppressive use in Crohn’s disease and on best practice in topics of current interest in Crohn’s disease. Methods: An International Steering Committee selected the top 10 most important unanswered practical questions on the use of conventional therapy in Crohn’s disease, to be debated and analysed in several National Meetings of different countries. In each country a National Steering Committee (NSC) was created to moderate a National Meeting during which several expert groups answered the selected questions in light of their clinical practice. Answers were classified according to the Oxford levels of evidence. Consensus: A general consensus was obtained, some of the conclusions were as follows. It is important to introduce conventional corticosteroids in moderate to severely active Crohn’s disease of any localization with initial duration of treatment varying according to patient’s response; the best option to prevent steroid-induced side effects is to avoid its prolonged or repetitive use and switching appropriate patients to immunosuppressive therapy. Initiation of immunomodulators early in the disease course should be considered for patients with a poor prognosis and optimal safety monitoring was discussed, with the need to reassess patients at appropriate timepoints, make corticosteroid-free remission a goal and treat beyond symptoms.
id RCAP_5ba6e65ad55c907432a3ec77e0b72253
oai_identifier_str oai:scielo:S0872-81782012000400005
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting resultsInflammatory bowel diseaseorticosteroidsCrohn’s diseaseConsensusIntroduction: The treatment of inflammatory bowel disease (IBD) has focussed on the management of symptoms but is becoming more resolute on changing the course of the disease and its complications in the long-term. In order to minimize the development of complications and to improve outcomes for these patients it is important to develop other strategies to manage IBD and to optimize current clinical practice. Objective: This article reports the main consensus statements reached during the Portuguese National Meeting on improvement of disease control in IBD, on optimization of corticosteroid and immunosuppressive use in Crohn’s disease and on best practice in topics of current interest in Crohn’s disease. Methods: An International Steering Committee selected the top 10 most important unanswered practical questions on the use of conventional therapy in Crohn’s disease, to be debated and analysed in several National Meetings of different countries. In each country a National Steering Committee (NSC) was created to moderate a National Meeting during which several expert groups answered the selected questions in light of their clinical practice. Answers were classified according to the Oxford levels of evidence. Consensus: A general consensus was obtained, some of the conclusions were as follows. It is important to introduce conventional corticosteroids in moderate to severely active Crohn’s disease of any localization with initial duration of treatment varying according to patient’s response; the best option to prevent steroid-induced side effects is to avoid its prolonged or repetitive use and switching appropriate patients to immunosuppressive therapy. Initiation of immunomodulators early in the disease course should be considered for patients with a poor prognosis and optimal safety monitoring was discussed, with the need to reassess patients at appropriate timepoints, make corticosteroid-free remission a goal and treat beyond symptoms.Sociedade Portuguesa de Gastrenterologia2012-07-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005Jornal Português de Gastrenterologia v.19 n.4 2012reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005Magro,FernandoCravo,MariliaLago,PaulaMinistro,PaulaPeixe,PaulaPortela,FranciscoRamos,JaimeTavares,Lourdesinfo:eu-repo/semantics/openAccess2024-02-06T17:09:10Zoai:scielo:S0872-81782012000400005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:21:17.122514Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
title Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
spellingShingle Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
Magro,Fernando
Inflammatory bowel disease
orticosteroids
Crohn’s disease
Consensus
title_short Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
title_full Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
title_fullStr Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
title_full_unstemmed Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
title_sort Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
author Magro,Fernando
author_facet Magro,Fernando
Cravo,Marilia
Lago,Paula
Ministro,Paula
Peixe,Paula
Portela,Francisco
Ramos,Jaime
Tavares,Lourdes
author_role author
author2 Cravo,Marilia
Lago,Paula
Ministro,Paula
Peixe,Paula
Portela,Francisco
Ramos,Jaime
Tavares,Lourdes
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Magro,Fernando
Cravo,Marilia
Lago,Paula
Ministro,Paula
Peixe,Paula
Portela,Francisco
Ramos,Jaime
Tavares,Lourdes
dc.subject.por.fl_str_mv Inflammatory bowel disease
orticosteroids
Crohn’s disease
Consensus
topic Inflammatory bowel disease
orticosteroids
Crohn’s disease
Consensus
description Introduction: The treatment of inflammatory bowel disease (IBD) has focussed on the management of symptoms but is becoming more resolute on changing the course of the disease and its complications in the long-term. In order to minimize the development of complications and to improve outcomes for these patients it is important to develop other strategies to manage IBD and to optimize current clinical practice. Objective: This article reports the main consensus statements reached during the Portuguese National Meeting on improvement of disease control in IBD, on optimization of corticosteroid and immunosuppressive use in Crohn’s disease and on best practice in topics of current interest in Crohn’s disease. Methods: An International Steering Committee selected the top 10 most important unanswered practical questions on the use of conventional therapy in Crohn’s disease, to be debated and analysed in several National Meetings of different countries. In each country a National Steering Committee (NSC) was created to moderate a National Meeting during which several expert groups answered the selected questions in light of their clinical practice. Answers were classified according to the Oxford levels of evidence. Consensus: A general consensus was obtained, some of the conclusions were as follows. It is important to introduce conventional corticosteroids in moderate to severely active Crohn’s disease of any localization with initial duration of treatment varying according to patient’s response; the best option to prevent steroid-induced side effects is to avoid its prolonged or repetitive use and switching appropriate patients to immunosuppressive therapy. Initiation of immunomodulators early in the disease course should be considered for patients with a poor prognosis and optimal safety monitoring was discussed, with the need to reassess patients at appropriate timepoints, make corticosteroid-free remission a goal and treat beyond symptoms.
publishDate 2012
dc.date.none.fl_str_mv 2012-07-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
dc.source.none.fl_str_mv Jornal Português de Gastrenterologia v.19 n.4 2012
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817551354685554688